AbbVie Inc (LTS:0QCV)
$ 174.92 -0.4 (-0.23%) Market Cap: 302.34 Bil Enterprise Value: 366.13 Bil PE Ratio: 60.57 PB Ratio: 51.09 GF Score: 86/100

Abbvie Inc at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 03:10PM GMT
Release Date Price: $60.26 (-0.01%)
David Reed Risinger
Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst

So thanks, everyone, for joining us for the AbbVie session. I first need to refer you to disclaimers at www.morganstanley.com/researchdisclosures. It is very much my pleasure to welcome Rick Gonzalez, who's Chairman and CEO; and also Rob Michael, who's the company's CFO, onstage today. Unfortunately, Mike Severino was originally on the schedule but he had a family health issue so he wasn't able to join today, but we're happy that you can be here. And I thought it would be great to just have you, Rick, kick it off with some opening remarks and then we'll go from there.

Richard A. Gonzalez
AbbVie Inc. - Chairman & CEO

Certainly, David. Thank you for having us. It's an exciting time, obviously, for AbbVie. We're in the midst of a major acquisition that we plan on consummating in the first quarter. And I think that strategy will continue to advance the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot